Triglycerides and Remnant Cholesterol Need More Focus:

The discussion highlighted the need for more potent therapies targeting remnant lipoproteins and triglycerides, such as ApoC3, ANGPTL3, and ANGPTL4 inhibitors, especially for patients with persistent hypertriglyceridemia despite LDL-C and non-HDL-C control.